PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)

Isabel Syndikus; Clare Cruickshank; John Staffurth; Alison Tree; Ann Henry; Olivia Naismith; Helen Mayles; Nicola Snelson; Shama Hassan; Stephanie Brown; Nuria Porta; Clare Griffin; Emma Hall

doi:10.1016/j.ctro.2020.08.003

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)

Clin Transl Radiat Oncol. 2020 Sep 1:25:22-28. doi: 10.1016/j.ctro.2020.08.003. eCollection 2020 Nov.

Authors

Affiliations

¹ The Clatterbridge Cancer Centre, Wirral, UK.
² Clinical Trials and Statistics Unit, The Institute of Cancer Research (ICR-CTSU), London, UK.
³ Cardiff University/Velindre Cancer Centre, Cardiff, UK.
⁴ The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, London, UK.
⁵ The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁶ National Radiotherapy Trials Quality Assurance Group, The Royal Marsden NHS Foundation Trust, London, UK.
⁷ National Radiotherapy Trials Quality Assurance Group, The Clatterbridge Cancer Centre, Wirral. UK.

Abstract

•PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres through the UK.

Abstract

Grants and funding